Skip to content

A randomized controlled trial and brain function study of acupuncture Treatment for unilateral sensorineural hearing loss

Study on the central mechanism of the effectiveness of acupuncture intervention in deafness from functional remodeling

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000375
Enrollment
Unknown
Registered
2025-02-20
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensorineural hearing loss

Interventions

acupuncture group:BU 20
SI 19 (affected side) GB 2(affected side) TE 17 (affected side) GB 12 (affected side)
LI 4 (bilateral) SI 6 (bilateral) TE 3 (bilateral).The needles were retained for 30 minutes with treatments administered 3 times a week for a total of 4 weeks.
Western medicine group:Mecobalamin tablets (Qixin produced by Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co. Ltd. specification: 0.5mg/tablet) were administered with 1 tablet ta

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of both Chinese and Western medicine and the onset is unilateral; (2) Aged between 18 and 75 years old (including 18 and 75 years old) with no gender restriction; (3) Ethnic Han right-handed with Chinese as the mother tongue; (4) The onset time is =3 weeks; (5) The patient understands and voluntarily accepts the treatment and has signed the informed consent form;

Exclusion criteria

Exclusion criteria: (1) Organic lesions of craniocerebral five senses; (2) Neuropsychiatric disorders history of taking psychotropic drugs; (3) Congenital deafness; deafness caused by genetic diseases; conductive deafness; mixed deafness; drug-induced deafness; cochlear or cerebellopontine angle space-occupying diseases; (4) Severe primary diseases such as cardiovascular cerebrovascular liver kidney and hematopoietic system diseases as well as tumors; (5) Participants who have taken part in other drug clinical trials within two months before enrollment; (6) Contraindications for magnetic resonance imaging; (7) Pregnant pre-pregnancy or breastfeeding women; (8) Unable to cooperate with inspection and treatment

Design outcomes

Primary

MeasureTime frame
Tinnitus Handicap Inventory;

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index;pure tone audiometry;TCM syndrome score scale;Self-rating depression scale;Minimum Mental State Examination;Self-Rating Anxiety Scale;

Countries

China

Contacts

Public ContactWeidong Shen

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

shenweidong1018@163.com13391019193

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026